Barclays PLC Increases Holdings in biote Corp. (NASDAQ:BTMD)

Barclays PLC raised its stake in biote Corp. (NASDAQ:BTMD) by 52.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,196 shares of the company’s stock after buying an additional 26,510 shares during the quarter. Barclays PLC owned approximately 0.14% of biote worth $432,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP boosted its holdings in biote by 1,016.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock valued at $4,931,000 after purchasing an additional 600,956 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in biote by 251.8% in the second quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock valued at $1,442,000 after acquiring an additional 138,200 shares during the last quarter. Wasatch Advisors LP grew its position in biote by 8.4% in the third quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock worth $7,772,000 after acquiring an additional 107,792 shares during the period. Sanders Morris Harris LLC increased its stake in biote by 131.2% during the third quarter. Sanders Morris Harris LLC now owns 180,965 shares of the company’s stock worth $1,010,000 after acquiring an additional 102,706 shares during the last quarter. Finally, State Street Corp raised its position in biote by 13.7% in the third quarter. State Street Corp now owns 475,491 shares of the company’s stock valued at $2,653,000 after purchasing an additional 57,290 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

biote Price Performance

Shares of NASDAQ BTMD opened at $5.64 on Friday. The business’s 50 day moving average is $6.17 and its two-hundred day moving average is $6.21. biote Corp. has a 52-week low of $3.65 and a 52-week high of $8.44. The firm has a market cap of $306.48 million, a price-to-earnings ratio of 21.69 and a beta of 1.08.

Analyst Ratings Changes

Separately, Craig Hallum assumed coverage on biote in a research report on Monday, December 16th. They set a “buy” rating and a $12.00 price objective for the company.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.